Coronaty artery disease with diabetes, including impaired glucose torelance
Conditions
Interventions
Administration of atorvastatin 20mg in the first 3 months, followed by the administration of atorvastatin 10mg and ezetimibe 10mg
Administration of atorvastatin 10mg and ezetimibe 10mg in the first 3
Sponsors
Cardiovascular Center, Anjo Kosei Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients who have a history of following coronary heart diseases; CABG or PCI was performed more than 6 months before >= 50% coronary artery stenosis according to the ACC/AHA classification was found by CAG 2) Diabetic patients under treatment or patients who diagnosed with diabetic (inclucing IGT; 2-hour plasma/serum glucose level: 140mg/dL to 199mg/dL) at 75g oral glucose tolerance test 3) Patients who take atorvastatin 10mg more than 3 months 4) Patients who are judged to require the more lipid-lowering therapy
Exclusion criteria
Exclusion criteria: 1) Patients with history of acute coronary syndrome within 6 months 2) Patients with inflammatory disease, infectious disease, and malignancy 3) Patients with history of hypersensitivity against ezetimibe and atorvastatin 4) Pregnant women, women who may be pregnant, and breast-feeding women. 5) Patients with severe liver dysfunction or renal dysfunction 6) Insulin-treated diabetic patients 7) Patients judged by the investigator/ sub investigator to be ineligible for some other reason
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change and percent change in MDA-LDL | — |
Secondary
| Measure | Time frame |
|---|---|
| Change and percent change in TC, LDL-C, TG, and HDL-C. Change and percent change in HbA1c | — |
Countries
Japan
Outcome results
None listed